{{Rsnum
|rsid=11568820
|Chromosome=12
|position=47908762
|Orientation=minus
|GMAF=0.4151
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 3.5 | 33.6 | 62.8
| HCB | 17.5 | 47.4 | 35.0
| JPT | 24.1 | 42.0 | 33.9
| YRI | 95.2 | 4.8 | 0.0
| ASW | 47.4 | 47.4 | 5.3
| CHB | 17.5 | 47.4 | 35.0
| CHD | 16.5 | 45.9 | 37.6
| GIH | 14.9 | 48.5 | 36.6
| LWK | 77.3 | 22.7 | 0.0
| MEX | 3.4 | 29.3 | 67.2
| MKK | 59.0 | 36.5 | 4.5
| TSI | 5.9 | 38.6 | 55.4
| HapMapRevision=28
}}

{{omim
|desc=VITAMIN D RECEPTOR; VDR
|id=601769
|rsnum=11568820
}}

{{PharmGKB
|RSID=rs11568820
|Name_s=VDR:Cdx2
|Gene_s=VDR
|Feature=
|Evidence=Web Resource:http://www.pharmgkb.org/search/annotatedGene/vdr/variant.jsp
|Annotation=In promoter; reduces the transcriptional activity; may be associated with prostate cancer risk.
|Drugs=
|Drug Classes=
|Diseases=Prostatic Neoplasms
|Curation Level=In-Depth
|PharmGKB Accession ID=PA161145144
}}

{{PMID Auto
|PMID=22306846
|Title=Vitamin D receptor and Alzheimer's disease: a genetic and functional study
}}

{{PMID Auto
|PMID=22213340
|Title=25-hydroxyvitamin D, vitamin D receptor gene polymorphisms, and severity of Parkinson's disease
}}

{{PMID Auto
|PMID=22729058
|Title=Vitamin D receptor polymorphisms in colorectal cancer in New Zealand: an association study
}}

{{PMID|17903296|OA=1
}} Genome-wide association with bone mass and geometry in the Framingham Heart Study.

{{PMID|18086759}} Vitamin D receptor gene polymorphisms and epithelial ovarian cancer risk.

{{PMID|18086783|OA=1
}} CDX2 VDR polymorphism and colorectal cancer.

{{PMID|18205531}} Vitamin D receptor gene haplotypes and susceptibility to HIV-1 infection in injection drug users.

{{PMID|18419802|OA=1
}} Vitamin D receptor gene polymorphisms and haplotypes and postmenopausal breast cancer risk.

{{PMID|18628249|OA=1
}} Association of vitamin D receptor gene variants, adiposity and colon cancer.

{{PMID|18709640}} Modification of the inverse association between dietary vitamin D intake and colorectal cancer risk by a FokI variant supports a chemoprotective action of Vitamin D intake mediated through VDR binding.

{{PMID|18936471|OA=1
}} Circulating 25-hydroxyvitamin D, VDR polymorphisms, and survival in advanced non-small-cell lung cancer.

{{PMID|18992263|OA=1
}} Colon tumor mutations and epigenetic changes associated with genetic polymorphism: insight into disease pathways.

{{PMID|19223536|OA=1
}} Polymorphisms in the vitamin D receptor and risk of ovarian cancer in four studies.

{{PMID|19255064|OA=1
}} Vitamin D-related genes, serum vitamin D concentrations and prostate cancer risk.

{{PMID|19309297}} Higher milk requirements for bone mineral accrual in adolescent girls bearing specific caucasian genotypes in the VDR promoter.

{{PMID|19450131|OA=1
}} Application of pharmacogenomics to vaccines.

{{PMID|19615888|OA=1
}} Vitamin D receptor gene polymorphisms, serum 25-hydroxyvitamin D levels, and melanoma: UK case-control comparisons and a meta-analysis of published VDR data.

{{PMID|19682379|OA=1
}} TagSNP transferability and relative loss of variability prediction from HapMap to an admixed population.

{{PMID|19841454|OA=1
}} Collaborative meta-analysis: associations of 150 candidate genes with osteoporosis and osteoporotic fracture.

{{PMID|20015871|OA=1
}} Pharmacogenetic risk factors for altered bone mineral density and body composition in pediatric acute lymphoblastic leukemia.

{{PMID|20361340|OA=1
}} Polymorphism in vitamin D receptor is associated with bone mineral density in patients with adolescent idiopathic scoliosis.

{{PMID|20432164|OA=1
}} Calcium, vitamin D, VDR genotypes, and epigenetic and genetic changes in rectal tumors.

{{PMID|21358824|OA=1
}} Prostate cancer susceptibility Loci identified on chromosome 12 in African Americans.

{{PMID|22170372|OA=1
}} Vitamin D receptor and megalin gene polymorphisms and their associations with longitudinal cognitive change in US adults.

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs11568820
|overall_frequency_n=68
|overall_frequency_d=128
|overall_frequency=0.53125
|n_genomes=39
|n_genomes_annotated=0
|n_haplomes=61
|n_articles=0
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{PMID Auto
|PMID=24381141
|Title=Vitamin D receptor gene polymorphisms and esophageal cancer risk in a Chinese population: a negative study
}}

{{PMID Auto
|PMID=22960018
|Title=Investigation of the vitamin D receptor gene (VDR) and its interaction with protein tyrosine phosphatase, non-receptor type 2 gene (PTPN2) on risk of islet autoimmunity and type 1 diabetes: the Diabetes Autoimmunity Study in the Young (DAISY).
|OA=1
}}

{{PMID Auto
|PMID=23300018
|Title=Vitamin D receptor genotype rs731236 (Taq1) and breast cancer prognosis.
}}

{{PMID Auto
|PMID=23546818
|Title=Vitamin D and calcium-sensing receptor polymorphisms differentially associate with resting energy expenditure in peripubertal children.
|OA=1
}}

{{PMID Auto
|PMID=25008423
|Title=Vitamin D receptor polymorphisms and susceptibility to Parkinson's disease and Alzheimer's disease: a meta-analysis
}}
{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}